Anxiolytics & ARVs

Legend

↑                  Potential elevated exposure of the anxiolytic therapy
↓                  Potential decreased exposure of the anxiolytic therapy
↔                No significant effect
D                  Potential decreased exposure of ARV drug
E                  Potential elevated exposure of ARV drug

ATV/c         ATV co-formulated with COBI (300/150 mg qd)
DRV/c         DRV co-formulated with COBI (800/150 mg qd)
CAB/RPV   CAB and RPV im long acting injections (PK and/or QT interactions shown are with RPV)

Numbers refer to increased or decreased AUC as observed in drug-drug interaction studies

BZD     benzodiazepines
SSRI    selective serotonin reuptake inhibitors
SNRI   serotonin and norepinephrine reuptake inhibitors

Interactions with ABC, FTC, 3TC, ZDV

ABC, FTC, 3TC, ZDV: no clinically relevant interactions expected.

Interactions with ibalizumab

None

Comments

1. ECG monitoring is recommended.
2. Caution as both drugs can induce QT interval prolongation

Further Information

For additional drug-drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, please refer to: http://www.hiv-druginteractions.org (University of Liverpool)